Felix Bachmann

USPTO Granted Patents = 19 (Patent Applications = 5)

CIPO Patents = 4 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 12)

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 18(Granted Patents)

Company Filing History:

16 out of 68

Basilea Pharmaceutica Ag

Basilea Pharmaceutica International Ag

patents

4. 1 out of 60

Ruprecht-karls-universitat Heidelberg

patents

5. 1 out of 1,179

Takeda Pharmaceutical Company Limited

patents

where one patent can have more than one assignee

Years Active: 2004-2022

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11419856 - Pharmaceutical combinations for use in the treatment of neoplastic diseases (2022-08-23),

2. 10724072 - Use of phospho-Akt as a biomarker of drug response (2020-07-28),

3. 10656162 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2020-05-19),

4. 10222377 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2019-03-05),

5. 10067120 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-09-04),

6. 10006078 - Use of phospho-Akt as a biomarker of drug response (2018-06-26),

7. 9995754 - Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles (2018-06-12),

8. 9970938 - Use of BUBR1 as a biomarker of drug response to furazanobenzimidazoles (2018-05-15),

9. 9476889 - Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles (2016-10-25),

10. 9366682 - Use of stathmin as a biomarker of drug response to furazanobenzimidazoles (2016-06-14),

11. 8802858 - Furazanobenzimidazoles as prodrugs to treat neoplastic or autoimmune diseases (2014-08-12),

12. 8486996 - Aroylfuranes and aroylthiophenes (2013-07-16),

13. 8288421 - Phenylaminopyridines (2012-10-16),

14. RE42890 - Furazanobenzimidazoles (2011-10-31),

15. 7951957 - Substituted benzimidazoles and their use for inducing apoptosis (2011-05-31),

Title: Innovative Contributions of Felix Bachmann in Pharmaceutical Patents

Introduction

Felix Bachmann, located in Basel, Switzerland, is a notable inventor with a remarkable portfolio of 19 patents. His expertise lies predominantly in the field of pharmaceutical innovations aimed at addressing neoplastic diseases. His contributions to the pharmaceutical arena significantly impact the development of novel treatment methodologies.

Latest Patents

Among his latest patents, Bachmann has developed pharmaceutical combinations intended for the treatment of neoplastic diseases. One key invention involves pharmaceutical combinations that include a compound of formula (I) featuring compounds such as phenyl or pyridinyl, with numerous potential substitutions to enhance efficacy, along with a compound of Formula (II) (eribulin) or pharmaceutically acceptable salts thereof. Additionally, he has patented the use of phospho-Akt as a biomarker for drug response prediction, focusing on specific phosphorylation sites to determine resistance to various compounds, establishing a pathway for improved therapeutic outcomes.

Career Highlights

Bachmann has made significant strides in his career, primarily through his work at esteemed companies such as Basilea Pharmaceutica AG and Novartis AG. His role as an inventor has placed him at the forefront of pharmaceutical research, leading to various breakthrough inventions in the treatment of both neoplastic and autoimmune diseases.

Collaborations

Throughout his career, Felix Bachmann has collaborated with notable professionals like Heidi Alexandra Lane and Martin Eberle. These partnerships have fostered a collaborative environment that has driven innovation and contributed to the successful development of groundbreaking therapies.

Conclusion

Felix Bachmann's innovative spirit and dedication to pharmaceutical research have culminated in numerous patents that advance the field of medical treatment. His work not only highlights the importance of patenting in the protection of intellectual property but also underscores the value of collaboration in scientific advancement. As he continues to explore new avenues in pharmaceutical innovation, his contributions will undoubtedly shape the future of treatment for neoplastic diseases.

This text is generated by artificial intelligence and may not be accurate.